
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded suppository containing ondansetron hydrochloride, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing ondansetron are listed in tablet, injection and solution forms. No finished ondansetron product of any kind is listed in suppository form.
Suppository bases differ, and the base used decides how USP <795> classifies the preparation for beyond-use dating. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Ondansetron is a serotonin 5-HT3 receptor blocker for nausea and vomiting that compounding pharmacies prepare as oral liquids, capsules and topical PLO gels.
Ondansetron is a selective antagonist at serotonin 5-HT3 receptors, which sit on vagal nerve endings in the gut and in the brain's chemoreceptor trigger zone; blocking them interrupts the signal that triggers vomiting. It is not a dopamine receptor antagonist. Manufactured products include ondansetron tablets, orally disintegrating tablets, oral solution and injection from many generic makers (for example Glenmark); the Zofran brand name does not currently appear in DailyMed. These products are FDA-approved to prevent nausea and vomiting from highly and moderately emetogenic chemotherapy, from radiotherapy to the abdomen or whole body, and after surgery. Prescribers may order ondansetron compounded as a liquid in a different concentration or flavor, in a capsule strength not manufactured, or as a topical gel for patients who cannot swallow. Compounded preparations are not FDA-approved and require a prescription.
Ondansetron labels carry no boxed warning. Do not use it with apomorphine, because of profound low blood pressure and loss of consciousness, or if you have had an allergic reaction to it. Ondansetron can lengthen the QT interval and has caused torsade de pointes; avoid it in congenital long QT syndrome and tell your prescriber about low potassium or magnesium, heart failure, slow heart rhythms, liver disease or other QT-prolonging drugs. Taken with serotonergic drugs such as SSRIs and SNRIs it can contribute to serotonin syndrome. The label also notes it can mask a worsening bowel obstruction and that the disintegrating tablet contains phenylalanine. Common effects are headache, constipation, tiredness and drowsiness. Pregnancy data are inconsistent, with no drug-associated miscarriage risk identified. It appears in breast milk at low levels with no infant effects reported. If side effects are severe or persist, talk to your prescriber or pharmacist.
Ondansetron antagonizes 5-HT3 receptors on peripheral vagal afferents (the predominant antiemetic site) and centrally in the area postrema; it has no dopamine receptor activity. Oral bioavailability is about 56 to 60 percent and is reported to be higher in cancer patients (StatPearls); protein binding is 70 to 76 percent; hepatic metabolism proceeds via CYP3A4 (predominant per the label), CYP1A2 and CYP2D6; elimination half-life is roughly 3 to 6 hours in healthy adults, longer with age, and about 20 hours in severe hepatic impairment, for which the label sets a daily maximum. Labeled indications (generic ondansetron tablets and ODT, Glenmark, revised 8/2025): prevention of nausea and vomiting with highly or moderately emetogenic chemotherapy, with abdominal or total body radiotherapy, and postoperatively. Prescribers have ordered ondansetron for refractory nausea and vomiting of pregnancy, cyclic vomiting syndrome in children and carcinoid-related diarrhea (StatPearls, 2023), and the International Journal of Pharmaceutical Compounding published an ondansetron hydrochloride pluronic lecithin organogel formulation for hospice and cancer patients (2000); data on transdermal absorption of that gel are limited. Dosing per prescriber. Monitoring: ECG and electrolytes with QT risk factors, serotonin syndrome symptoms with serotonergic agents, signs of ileus, and pain control when co-prescribed with tramadol.
Wash your hands. If the suppository is soft, chill it in its wrapper in the refrigerator or under cool water for a few minutes, then unwrap it. For rectal use, coat the tip with a water-soluble lubricant (not petroleum jelly), lie on your side with your upper knee bent, and insert it pointed end first past the muscle at the opening. For vaginal use, lie on your back with knees bent and insert it as far as it comfortably goes, by finger or applicator; bedtime use limits leakage, and a panty liner protects clothing. Stay lying down about 15 minutes. Wash your hands.
Suppositories are nonaqueous, so under USP <795> they can carry a beyond-use date of up to 180 days at controlled room temperature or in the refrigerator when no other stability data apply. Storage depends on the base: fatty bases can soften at room temperature and may be labeled for the refrigerator, while polyethylene glycol bases usually do not need refrigeration. Keep them cool so they do not melt, and refrigerate them if your label says to.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Insert 1 unwrapped suppository